KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Net Income: 2009-2025

Historic Net Income for Jazz Pharmaceuticals (JAZZ) over the last 16 years, with Sep 2025 value amounting to $251.5 million.

  • Jazz Pharmaceuticals' Net Income rose 16.77% to $251.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $565.9 million, marking a year-over-year increase of 21.63%. This contributed to the annual value of $561.8 million for FY2024, which is 34.45% up from last year.
  • Jazz Pharmaceuticals' Net Income amounted to $251.5 million in Q3 2025, which was up 373.29% from -$92.0 million recorded in Q2 2025.
  • In the past 5 years, Jazz Pharmaceuticals' Net Income registered a high of $251.5 million during Q3 2025, and its lowest value of -$364.7 million during Q2 2021.
  • Moreover, its 3-year median value for Net Income was $126.4 million (2023), whereas its average is $113.9 million.
  • As far as peak fluctuations go, Jazz Pharmaceuticals' Net Income plummeted by 641.83% in 2022, and later soared by 1,116.53% in 2023.
  • Over the past 5 years, Jazz Pharmaceuticals' Net Income (Quarterly) stood at -$32.3 million in 2021, then crashed by 641.83% to -$240.0 million in 2022, then soared by 139.43% to $94.6 million in 2023, then spiked by 102.01% to $191.1 million in 2024, then rose by 16.77% to $251.5 million in 2025.
  • Its last three reported values are $251.5 million in Q3 2025, -$92.0 million for Q2 2025, and $191.1 million during Q4 2024.